Arcturus Therapeutics Holdings Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| SASSINE ANDY | Chief Financial Officer | Purchase | 1,238 | $16.56 | $20,501 | 221,764 | Aug 15, 2025 |
| SASSINE ANDY | Chief Financial Officer | Purchase | 1,238 | $16.56 | $20,501 | 221,764 | Aug 15, 2025 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 12,000 | $20.76 | $249,120 | 435,334 | Oct 15, 2024 |
| Marantz Jing L. | — | Option Exercise | 3,131 | — | — | 3,131 | Jun 14, 2024 |
| HOLMES EDWARD W | — | Option Exercise | 3,131 | — | — | 3,131 | Jun 14, 2024 |
| Markels John | — | Option Exercise | 3,131 | — | — | 3,131 | Jun 14, 2024 |
| Marquet Magda | — | Option Exercise | 3,131 | — | — | 3,131 | Jun 14, 2024 |
| BARLOW JAMES F | — | Option Exercise | 3,131 | — | — | 13,131 | Jun 14, 2024 |
| FARRELL PETER C | — | Option Exercise | 3,131 | — | — | 55,741 | Jun 14, 2024 |
| SASSINE ANDY | Chief Financial Officer | Sale | 50,000 | $32.03 | $1,601,500 | 220,526 | Jun 12, 2024 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 114 | $45.00 | $5,130 | 447,334 | Jun 5, 2024 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 26,000 | $40.01 | $1,040,260 | 447,448 | Jun 3, 2024 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 17,435 | $35.02 | $610,574 | 473,448 | Mar 25, 2024 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 8,565 | $35.01 | $299,861 | 490,883 | Mar 19, 2024 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $18.72 | $93,600 | 499,448 | Nov 1, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $25.61 | $128,050 | 504,448 | Oct 2, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $31.45 | $157,250 | 509,448 | Sep 1, 2023 |
| SASSINE ANDY | Chief Financial Officer | Award / Grant | 1,223 | $17.37 | $21,244 | 270,526 | Aug 15, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $34.91 | $174,550 | 514,448 | Aug 1, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 25,000 | $35.01 | $875,250 | 519,448 | Jul 14, 2023 |
| Kummerfeld Keith C | See Remarks | Option Exercise | 1,437 | $4.99 | $7,171 | 6,887 | Jul 14, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $28.75 | $143,750 | 544,448 | Jul 3, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $27.16 | $135,800 | 549,448 | Jun 1, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 17,075 | $30.00 | $512,250 | 562,373 | May 11, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $25.93 | $129,650 | 579,448 | May 1, 2023 |
| Kummerfeld Keith C | See Remarks | Option Exercise | 1,031 | $14.12 | $14,558 | 1,981 | Apr 18, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $25.38 | $126,900 | 584,448 | Apr 3, 2023 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 5,000 | $16.07 | $80,350 | 589,448 | Mar 6, 2023 |
| Marquet Magda | — | Purchase | 2,222 | $18.00 | $39,996 | 24,942 | Dec 15, 2022 |
| Payne Joseph E | President and CEO | Purchase | 5,000 | $16.51 | $82,550 | 1,480,097 | Nov 23, 2022 |
| SASSINE ANDY | Chief Financial Officer | Award / Grant | 1,068 | $18.42 | $19,673 | 269,303 | Aug 15, 2022 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 8,100 | $40.00 | $324,000 | 594,448 | Jan 4, 2022 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 3,633 | $40.00 | $145,320 | 602,548 | Dec 16, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 6,367 | $40.00 | $254,680 | 606,181 | Dec 8, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $44.41 | $444,100 | 612,548 | Nov 1, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $44.36 | $443,600 | 622,548 | Oct 1, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $55.86 | $558,600 | 632,548 | Sep 1, 2021 |
| Ultragenyx Pharmaceutical Inc. | — | Sale | 725,000 | $55.44 | $40,194,000 | 1,475,000 | Aug 11, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $40.07 | $400,700 | 642,548 | Aug 3, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $42.95 | $429,500 | 652,548 | Apr 1, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $54.23 | $542,300 | 662,548 | Mar 1, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $75.31 | $753,100 | 672,548 | Feb 1, 2021 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $46.40 | $464,000 | 682,548 | Jan 4, 2021 |
| Ultragenyx Pharmaceutical Inc. | — | Sale | 442,255 | $105.54 | $46,675,593 | 2,557,745 | Dec 9, 2020 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $96.19 | $961,900 | 692,548 | Dec 1, 2020 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $55.28 | $552,800 | 702,548 | Nov 2, 2020 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $42.83 | $428,300 | 712,548 | Oct 1, 2020 |
| Chivukula Pad | Chief Scientific Officer & COO | Sale | 10,000 | $45.16 | $451,600 | 722,548 | Sep 3, 2020 |
| Kummerfeld Keith C | See Remarks | Purchase | 450 | $33.33 | $14,999 | 950 | Jun 12, 2020 |
| Payne Joseph E | President and CEO | Purchase | 1,000 | $31.69 | $31,690 | 1,475,097 | Jun 10, 2020 |